Acrivon Therapeutics, Inc. (ACRV)
(Delayed Data from NSDQ)
$7.33 USD
-0.23 (-3.04%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $7.33 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ACRV 7.33 -0.23(-3.04%)
Will ACRV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ACRV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACRV
Verastem (VSTM) Begins Dosing in Solid Tumors Study in China
AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU
ACRV: What are Zacks experts saying now?
Zacks Private Portfolio Services
SpringWorks (SWTX) Rises More Than 40% in a Year: Here's Why
Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up
Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
Other News for ACRV
Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?
Optimistic Buy Rating for Acrivon Therapeutics Based on Promising ACR-2316 Prospects and Innovative AP3 Platform
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
Acrivon Therapeutics: A Buy Rating on Strong Clinical and Financial Prospects
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024